A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the Glaxo Smith Kline (GSK) Herpes Zoster Recombinant HZ/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients

Trial Profile

A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the Glaxo Smith Kline (GSK) Herpes Zoster Recombinant HZ/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs GSK 1437173A (Primary) ; Varicella zoster virus vaccine live
  • Indications Herpes zoster; Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 11 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
    • 02 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top